Myokardia Inc (NASDAQ:MYOK) insider Joseph Lambing sold 5,000 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider now directly owns 95,846 shares of the company’s stock, valued at $4,792,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Myokardia Inc (NASDAQ MYOK) traded down $0.55 during trading hours on Friday, hitting $47.50. 334,187 shares of the stock were exchanged, compared to its average volume of 448,635. Myokardia Inc has a 1-year low of $10.80 and a 1-year high of $55.40. The stock has a market capitalization of $1,831.73, a PE ratio of -62.50 and a beta of 4.00.
Myokardia (NASDAQ:MYOK) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting analysts’ consensus estimates of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The business had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $6.10 million. During the same period in the prior year, the company earned ($0.35) earnings per share. The business’s revenue was up 58.6% compared to the same quarter last year. analysts anticipate that Myokardia Inc will post -1.62 earnings per share for the current year.
A number of equities research analysts recently weighed in on MYOK shares. Zacks Investment Research raised shares of Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. TheStreet cut shares of Myokardia from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. ValuEngine cut shares of Myokardia from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. started coverage on shares of Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 target price for the company. Finally, BidaskClub raised shares of Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $55.67.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in Myokardia by 37.2% during the fourth quarter. BlackRock Inc. now owns 1,920,651 shares of the biotechnology company’s stock worth $80,859,000 after purchasing an additional 521,031 shares in the last quarter. Vanguard Group Inc. raised its holdings in Myokardia by 11.5% during the second quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after purchasing an additional 78,800 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Myokardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after purchasing an additional 242,408 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after purchasing an additional 398,900 shares in the last quarter. Finally, VHCP Management II LLC purchased a new position in Myokardia during the third quarter worth about $11,355,000. 63.82% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Myokardia Inc (NASDAQ:MYOK) Insider Sells $250,000.00 in Stock” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://ledgergazette.com/2018/02/10/joseph-lambing-sells-5000-shares-of-myokardia-inc-myok-stock.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.